Aeglea BioTherapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch AGLE and buy or sell other stocks, ETFs, and their options commission-free!About AGLE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.
CEOCameron Turtle, PhD
CEOCameron Turtle, PhD
Employees65
Employees65
HeadquartersWaltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded2013
Founded2013
Employees65
Employees65
AGLE Key Statistics
Market cap714.81M
Market cap714.81M
Price-Earnings ratio-10.76
Price-Earnings ratio-10.76
Dividend yield—
Dividend yield—
Average volume636.28K
Average volume636.28K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$33.47
52 Week high$33.47
52 Week low$10.91
52 Week low$10.91
Stock Snapshot
As of today, Aeglea BioTherapeutics(AGLE) shares are valued at $11.75. The company's market cap stands at 714.81M, with a P/E ratio of -10.76.
During the trading day, Aeglea BioTherapeutics(AGLE) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading activity shows a volume of 0, compared to an average daily volume of 636.28K.
The stock's 52-week range extends from a low of $10.91 to a high of $33.47.
The stock's 52-week range extends from a low of $10.91 to a high of $33.47.
People also own
Based on the portfolios of people who own AGLE. This list is generated using Robinhood data, and it’s not a recommendation.